COMP <GO>
LSTA vs LTRN // REVENUE GROWTH (YOY)
Lisata Therapeutics Inc. (NASDAQ) VS. Lantern Pharma Inc. (NASDAQ) • 15-METRIC TALLY: LSTA 0
— LTRN 1
■ METRIC PARITY
LAST: $1.01 (-4.72%) • MKT CAP: $10.9M
revenue-growth
-65.00%
LAST: $0.73 (-5.52%) • MKT CAP: $10.9M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LSTA VS. LTRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LSTA | LTRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.1 | 38.1 | 0.00 | TIE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.9M | $10.9M | -$5.8K | LTRN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LSTA REV | LTRN REV | LSTA GROSS % | LTRN GROSS % | LSTA FCF | LTRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $170.0K | $0 | — | — | -$16.0M | -$15.7M |
| FY 2024 | $1.0M | $0 | — | — | -$19.4M | -$17.8M |
| FY 2023 | $0 | $0 | — | — | -$20.0M | -$14.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LSTA // BETA —
LTRN // BETA —